Antineoplastic Agents/administration & dosage; Antineoplastic Agents/pharmacokinetics; Focal Adhesion Kinase 1/antagonists & inhibitors; Focal Adhesion Kinase 2/antagonists & inhibitors; Molecular Targeted Therapy; Neoplasms/drug therapy; Protein Kinase Inhibitors/administration & dosage; Protein Kinase Inhibitors/pharmacokinetics; Pyrimidines/administration & dosage; Pyrimidines/pharmacokinetics; Sulfonamides/administration & dosage; Sulfonamides/pharmacokinetics; Adult; Aged; Aged, 80 and over; Antineoplastic Agents/adverse effects; Australia; Canada; Cytochrome P-450 CYP3A/metabolism; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors/administration & dosage; Enzyme Inhibitors/pharmacokinetics; Female; Fluorodeoxyglucose F18; Focal Adhesion Kinase 1/metabolism; Focal Adhesion Kinase 2/metabolism; Humans; Male; Maximum Tolerated Dose; Midazolam/metabolism; Middle Aged; Neoplasm Staging; Neoplasms/diagnostic imaging; Neoplasms/enzymology; Neoplasms/pathology; Nonlinear Dynamics; Positron-Emission Tomography; Protein Kinase Inhibitors/adverse effects; Pyrimidines/adverse effects; Radiopharmaceuticals; Sulfonamides/adverse effects; Treatment Outcome; United States